Arlington Trust Co LLC Sells 832 Shares of Edwards Lifesciences Co. (NYSE:EW)

Arlington Trust Co LLC lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 6.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 11,450 shares of the medical research company’s stock after selling 832 shares during the period. Arlington Trust Co LLC’s holdings in Edwards Lifesciences were worth $1,058,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of EW. DSM Capital Partners LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth about $28,000. Crewe Advisors LLC bought a new stake in Edwards Lifesciences during the 1st quarter worth approximately $28,000. First Community Trust NA acquired a new stake in Edwards Lifesciences during the 2nd quarter valued at $29,000. Riverview Trust Co acquired a new stake in Edwards Lifesciences during the 1st quarter valued at $34,000. Finally, Pingora Partners LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $66.81 on Friday. The firm’s 50 day simple moving average is $74.75 and its 200 day simple moving average is $84.15. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a market capitalization of $40.26 billion, a price-to-earnings ratio of 28.80, a P/E/G ratio of 2.92 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same period last year, the business posted $0.66 earnings per share. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.7 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on EW shares. The Goldman Sachs Group decreased their target price on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Daiwa America upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, July 31st. StockNews.com downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Stifel Nicolaus decreased their price target on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. Finally, Evercore ISI lowered their price target on shares of Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating for the company in a report on Thursday, July 25th. Fourteen research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $82.10.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $4,378,659.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $4,378,659.44. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,250 shares of company stock worth $1,321,988. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.